Access cutting-edge prostate cancer treatment through this clinical trial at a research site in Germantown. Study-provided care at no cost to qualified participants.
Access prostate cancer specialists in Germantown at no cost
This study follows strict safety protocols and ethical guidelines
All study-related prostate cancer treatment provided free
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this prostate cancer clinical trial in Germantown, TN
If you're searching for prostate cancer treatment options in Germantown, TN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Germantown research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.